CR20150456A - Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen - Google Patents

Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen

Info

Publication number
CR20150456A
CR20150456A CR20150456A CR20150456A CR20150456A CR 20150456 A CR20150456 A CR 20150456A CR 20150456 A CR20150456 A CR 20150456A CR 20150456 A CR20150456 A CR 20150456A CR 20150456 A CR20150456 A CR 20150456A
Authority
CR
Costa Rica
Prior art keywords
novedosos
abexinostate
salt
pharmaceutical compositions
compositions containing
Prior art date
Application number
CR20150456A
Other languages
English (en)
Inventor
Anne Pimont-Garro
Philippe Letellier
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48521256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150456(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of CR20150456A publication Critical patent/CR20150456A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

Tosilato abexinostato de la fórmula II y la forma I cristalina de este caracterizado por el patrón de difracción X en polvo del mismo, el espectro de Raman de este y el espectro de NMR CP/MAS 13C en estado sólido.
CR20150456A 2013-03-04 2015-09-02 Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen CR20150456A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772191P 2013-03-04 2013-03-04
FR1351898A FR3002733B1 (fr) 2013-03-04 2013-03-04 Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2014/050455 WO2014135776A1 (fr) 2013-03-04 2014-03-03 Nouveau sel de l'abexinostat, forme cristalline associee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
CR20150456A true CR20150456A (es) 2015-10-21

Family

ID=48521256

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150456A CR20150456A (es) 2013-03-04 2015-09-02 Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen

Country Status (39)

Country Link
US (3) US9115108B2 (es)
EP (2) EP3252044A1 (es)
JP (2) JP6449177B2 (es)
CN (2) CN105263917B (es)
AR (1) AR094935A1 (es)
AU (2) AU2014224456B2 (es)
BR (1) BR112015021443A2 (es)
CA (1) CA2903369C (es)
CL (1) CL2015002488A1 (es)
CR (1) CR20150456A (es)
CY (1) CY1119147T1 (es)
DK (1) DK2964622T3 (es)
DO (1) DOP2015000215A (es)
EA (2) EA030689B1 (es)
ES (1) ES2632471T3 (es)
FR (1) FR3002733B1 (es)
GE (1) GEP201706760B (es)
HK (1) HK1220965A1 (es)
HR (1) HRP20171041T1 (es)
HU (1) HUE035299T2 (es)
IL (1) IL241038B (es)
JO (1) JO3402B1 (es)
LT (1) LT2964622T (es)
MA (1) MA38423B1 (es)
ME (1) ME02814B (es)
MX (1) MX355436B (es)
MY (1) MY192027A (es)
NI (1) NI201500122A (es)
PE (1) PE20151591A1 (es)
PL (1) PL2964622T3 (es)
PT (1) PT2964622T (es)
RS (1) RS56224B1 (es)
SG (1) SG11201506952YA (es)
SI (1) SI2964622T1 (es)
TN (1) TN2015000367A1 (es)
TW (1) TWI506023B (es)
UA (1) UA118550C2 (es)
UY (1) UY35356A (es)
WO (1) WO2014135776A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113343A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AP2015008381A0 (en) 2012-11-02 2015-04-30 Pfizer Bruton's tyrosine kinase inhibitors
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
AU2015311905B2 (en) * 2014-09-03 2020-03-05 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl)-N-{2-(4-(hydroxycarbamoyl) phenoxy)ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
FR3025196B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3025197B1 (fr) * 2014-09-03 2019-09-06 Pharmacyclics, Inc. Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2022261401A1 (en) 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
AU2004230889B2 (en) * 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PT2964622T (pt) 2017-07-13
CL2015002488A1 (es) 2016-03-11
BR112015021443A2 (pt) 2017-07-18
US20170313671A1 (en) 2017-11-02
GEP201706760B (en) 2017-10-25
HUE035299T2 (en) 2018-05-02
EA201891023A1 (ru) 2019-03-29
AU2014224456A8 (en) 2015-10-22
MY192027A (en) 2022-07-23
CN105263917B (zh) 2018-11-20
EP3252044A1 (fr) 2017-12-06
TN2015000367A1 (fr) 2017-01-03
US9115108B2 (en) 2015-08-25
EA030689B1 (ru) 2018-09-28
WO2014135776A1 (fr) 2014-09-12
MA38423A1 (fr) 2017-02-28
AU2014224456A1 (en) 2015-10-08
JP6449177B2 (ja) 2019-01-09
DOP2015000215A (es) 2015-09-30
JP2016510735A (ja) 2016-04-11
US10150748B2 (en) 2018-12-11
UY35356A (es) 2014-09-30
PL2964622T3 (pl) 2017-10-31
NI201500122A (es) 2018-10-18
FR3002733B1 (fr) 2015-08-14
US20150315167A1 (en) 2015-11-05
MX2015011566A (es) 2016-06-24
CN109734690B (zh) 2023-08-11
HK1220965A1 (zh) 2017-05-19
JO3402B1 (ar) 2019-10-20
AU2018202881A1 (en) 2018-05-17
RS56224B1 (sr) 2017-11-30
EP2964622B1 (fr) 2017-04-19
AU2014224456B2 (en) 2018-01-25
MA38423B1 (fr) 2017-10-31
DK2964622T3 (en) 2017-07-31
CN105263917A (zh) 2016-01-20
EA039113B1 (ru) 2021-12-06
CY1119147T1 (el) 2018-02-14
TW201434822A (zh) 2014-09-16
ES2632471T3 (es) 2017-09-13
AU2018202881B2 (en) 2020-02-27
TWI506023B (zh) 2015-11-01
CN109734690A (zh) 2019-05-10
MX355436B (es) 2018-04-18
AR094935A1 (es) 2015-09-09
JP6720280B2 (ja) 2020-07-08
LT2964622T (lt) 2017-08-10
SG11201506952YA (en) 2015-10-29
IL241038A0 (en) 2015-11-30
EP2964622A1 (fr) 2016-01-13
FR3002733A1 (fr) 2014-09-05
US20140249215A1 (en) 2014-09-04
IL241038B (en) 2019-09-26
HRP20171041T1 (hr) 2017-10-06
CA2903369A1 (en) 2014-09-12
PE20151591A1 (es) 2015-11-06
NZ712380A (en) 2020-10-30
EA201591530A1 (ru) 2016-01-29
ME02814B (me) 2018-01-20
SI2964622T1 (sl) 2017-10-30
CA2903369C (en) 2021-06-08
UA118550C2 (uk) 2019-02-11
JP2019069955A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
CR20150456A (es) Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
PH12015502814B1 (en) 4-membered ring carboxamides used as nematicides
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
ECSP14013215A (es) Compuestos novedosos
NI201500096A (es) Compuesto químicos
CR20160016A (es) Pirazolpiridinas sustituidas
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
NI201600016A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los continen.
TN2016000490A1 (en) Naphthyridinedione derivatives.
DOP2016000293A (es) Derivados de diheterociclo enlazado a cicloalquilo
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
NI201200194A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
DOP2015000299A (es) Derivados de prodroga de triazolpiridinas sustituidas
MX2015014470A (es) Analogos de combretastatina.
MX2016000487A (es) Piridina-2-carboxamidas como nematicidas.
UY35958A (es) Derivados de quinolina como insecticidas y acaricidas
UY35999A (es) Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas